Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Organogenesis Holdings Inc. (ORGO) Market Cap & Valuation Ratios

Organogenesis Holdings Inc. (ORGO) has a market cap of $127.8M and a price-to-sales ratio of 0.3, with earnings according to EquiReason's reading of its SEC filings.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

ORGOOrganogenesis Holdings Inc.Follow ORGO — free
Drug Manufacturers - Specialty & Generic · Healthcare
—
Price chart with a free account
Market cap
127.8M
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
5 Nov, in 12 days

Peers

drug manufacturers - specialty & generic · nearest by market cap · trailing 12 months
CompanyMkt cap, $BP/EEV/SalesEV/EBITDAFCF yieldRev. growthOp. marginROIC
ORGO0.1—0.2—16.3%+7%-8%-27%
AQST0.5—8.4—-9.2%+23%-98%—
EOLS0.5—1.8—-4.7%+14%-6%-26%
TLRY0.4—0.4——+16%-9%-6%
EBS0.3—1.026.8—-10%-9%-8%
ANIK0.3—2.1496.50.2%+5%-4%-5%
CGC0.3————+7%-55%-26%
BIOA0.2————+168%—-56%
SIGA0.2—2.0—-9.1%-70%-21%-30%
GLAS0.2—1.3—-8.5%-9%-9%-14%
AKBA0.2—0.2——+8%-7%—
Median of these 10—1.5261.7-8.5%+7%-9%-20%

; EV/Sales 0.2 vs. 1.5.

Growth vs. price

each dot a company · hover or tap for values

Organogenesis Holdings Inc. — questions

What is Organogenesis Holdings Inc.'s market cap?
$127.8M.
What is Organogenesis Holdings Inc.'s price-to-sales ratio?
0.3.

Every figure on this page comes from Organogenesis Holdings Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.